My doctor has just started me on 10 mg of Zyprexa and my biggest fear is getting Diabetes. I am Bi Polar and also take 100 mg Lamictal .5 mg Clonazepam 25 mg Hydroxyzine Pamoate. I am 65 years old and have been diaganosed with Bi Polar II at age 45. Since then I have been struggling with finding the right medication for my depression.
What is the percentage of people who get Diabetes while taking Zyprexa?
- 4 Mar 2011 by BUTCHIE III
- 4 Mar 2011
- lamictal, zyprexa, depression, bipolar disorder, anxiety, benzodiazepine withdrawal, insomnia, obsessive compulsive disorder, panic disorder, restless legs syndrome, periodic limb movement disorder, clonazepam, hydroxyzine, fear
Hey BUTCHIE III,
While Zyprexa is considered safer than its predecessors like Haldol, it still has side effects that you need to be aware of. The extensive info that I found includes the following:
Physicians should consider the risks and benefits when prescribing olanzapine to patients with an established diagnosis of diabetes mellitus, or having borderline increased blood glucose level (fasting 100-126 mg/dL, non-fasting 140-200 mg/dL). Patients taking olanzapine should be monitored regularly for worsening of glucose control. Patients starting treatment with olanzapine should undergo fasting blood glucose testing at the beginning of treatment and periodically during treatment. Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing. In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the suspect drug [see Patient Counseling Information (17.4)].
Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotics including olanzapine. Assessment of the relationship between atypical antipsychotic use and glucose abnormalities is complicated by the possibility of an increased background risk of diabetes mellitus in patients with schizophrenia and the increasing incidence of diabetes mellitus in the general population. Epidemiological studies suggest an increased risk of treatment-emergent hyperglycemia-related adverse reactions in patients treated with the atypical antipsychotics. While relative risk estimates are inconsistent, the association between atypical antipsychotics and increases in glucose levels appears to fall on a continuum and olanzapine appears to have a greater association than some other atypical antipsychotics.
Mean increases in blood glucose have been observed in patients treated (median exposure of 9.2 months) with olanzapine in phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). The mean increase of serum glucose (fasting and nonfasting samples) from baseline to the average of the 2 highest serum concentrations was 15.0 mg/dL.
In a study of healthy volunteers, subjects who received olanzapine (N=22) for 3 weeks had a mean increase compared to baseline in fasting blood glucose of 2.3 mg/dL. Placebo-treated subjects (N=19) had a mean increase in fasting blood glucose compared to baseline of 0.34 mg/dL.
Olanzapine Monotherapy in Adults — In an analysis of 5 placebo-controlled adult olanzapine monotherapy studies with a median treatment duration of approximately 3 weeks, olanzapine was associated with a greater mean change in fasting glucose levels compared to placebo (2.76 mg/dL versus 0.17 mg/dL). The difference in mean changes between olanzapine and placebo was greater in patients with evidence of glucose dysregulation at baseline (patients diagnosed with diabetes mellitus or related adverse reactions, patients treated with anti-diabetic agents, patients with a baseline random glucose level ≥200 mg/dL, and/or a baseline fasting glucose level ≥126 mg/dL). Olanzapine-treated patients had a greater mean HbA1c increase from baseline of 0.04% (median exposure 21 days), compared to a mean HbA1c decrease of 0.06% in placebo-treated subjects (median exposure 17 days).
In an analysis of 8 placebo-controlled studies (median treatment exposure 4-5 weeks), 6.1% of olanzapine-treated subjects (N=855) had treatment-emergent glycosuria compared to 2.8% of placebo-treated subjects (N=599). Table 2 shows short-term and long-term changes in fasting glucose levels from adult olanzapine monotherapy studies.
Table 2: Changes in Fasting Glucose Levels from Adult Olanzapine Monotherapy Studies
a Not Applicable.
Up to 12 weeks exposure At least 48 weeks exposure
Laboratory Analyte Category Change (at least once)
from Baseline Treatment Arm N Patients N Patients
Glucose Normal to High
(<100 mg/dL to ≥126 mg/dL) Olanzapine 543 2.2% 345 12.8%
Placebo 293 3.4% NAa NAa
Borderline to High
(≥100 mg/dL and <126 mg/dL to ≥126 mg/dL) Olanzapine 178 17.4% 127 26.0%
Placebo 96 11.5% NAa NAa
The mean change in fasting glucose for patients exposed at least 48 weeks was 4.2 mg/dL (N=487). In analyses of patients who completed 9-12 months of olanzapine therapy, mean change in fasting and nonfasting glucose levels continued to increase over time.
- Lamictal Drug Information
- Zyprexa Drug Information
- Clonazepam Drug Information
- Hydroxyzine Drug Information
Search for questions
Still looking for answers? Try searching for what you seek or ask your own question.
Posted 17 Dec 2009 • 3 answers
Posted 12 Dec 2010 • 1 answer
Posted 17 Oct 2011 • 2 answers
Posted 2 Jan 2012 • 3 answers
Posted 2 Mar 2016 • 3 answers